Literature DB >> 9648353

Priority during a meningitis epidemic: vaccination or treatment?

H Veeken1, K Ritmeijer, B Hausman.   

Abstract

From November 1995 to May 1996, a meningitis epidemic occurred in northern Nigeria. More than 75,000 cases and 8440 deaths (case fatality rate (CFR), 11%) were recorded. Médecins sans Frontières, in cooperation with the Nigerian government, carried out an assistance programme (support to case management, surveillance and mass vaccination) in three states (Bauchi, Kano, Katsina) where 75% of cases occurred. Cost analysis of this assistance in Katsina State reveals that case management and mass vaccination were efficient: US$ 35 per case treated and US$ 0.64 per vaccination. There was, however, a remarkable difference in cost-effectiveness between the two strategies. The cost per death averted by improved case treatment was estimated to be US$ 396, while the cost per death averted by vaccination was estimated to be US$ 6000. In large part this difference is attributed to the late start of vaccination: more than 6 weeks after the epidemic threshold had been passed. During meningitis epidemics in countries where surveillance systems are inadequate, such as in most of sub-Saharan Africa, curative programmes should have priority.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9648353      PMCID: PMC2305636     

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  4 in total

1.  [Physicians without borders and the meningitis epidemic in Niger in 1995: vaccinate or treat?].

Authors:  K Ritmeijer
Journal:  Ned Tijdschr Geneeskd       Date:  1996-08-03

2.  Age-specific differences in duration of clinical protection after vaccination with meningococcal polysaccharide A vaccine.

Authors:  A L Reingold; C V Broome; A W Hightower; G W Ajello; G A Bolan; C Adamsbaum; E E Jones; C Phillips; H Tiendrebeogo; A Yada
Journal:  Lancet       Date:  1985-07-20       Impact factor: 79.321

Review 3.  Meningococcal meningitis in sub-Saharan Africa: a model for the epidemic process.

Authors:  P S Moore
Journal:  Clin Infect Dis       Date:  1992-02       Impact factor: 9.079

4.  Epidemic meningococcal disease in Nairobi, Kenya, 1989. The Kenya/Centers for Disease Control (CDC) Meningitis Study Group.

Authors:  R W Pinner; F Onyango; B A Perkins; N B Mirza; D M Ngacha; M Reeves; W DeWitt; E Njeru; N N Agata; C V Broome
Journal:  J Infect Dis       Date:  1992-08       Impact factor: 5.226

  4 in total
  6 in total

Review 1.  The state of health economic evaluation research in Nigeria: a systematic review.

Authors:  Paul Gavaza; Karen L Rascati; Abiola O Oladapo; Star Khoza
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

Review 2.  Update on meningococcal disease with emphasis on pathogenesis and clinical management.

Authors:  M van Deuren; P Brandtzaeg; J W van der Meer
Journal:  Clin Microbiol Rev       Date:  2000-01       Impact factor: 26.132

Review 3.  Review of the cost effectiveness of immunisation strategies for the control of epidemic meningococcal meningitis.

Authors:  Mark A Miller; Cathryn K Shahab
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

4.  Updating the evidence base on the operational costs of supplementary immunization activities for current and future accelerated disease control, elimination and eradication efforts.

Authors:  Gian Gandhi; Patrick Lydon
Journal:  BMC Public Health       Date:  2014-01-22       Impact factor: 3.295

5.  Meningococcal disease and climate.

Authors:  Helena Palmgren
Journal:  Glob Health Action       Date:  2009-11-11       Impact factor: 2.640

Review 6.  Meningitis in HIV-positive patients in sub-Saharan Africa: a review.

Authors:  Jennifer A Veltman; Claire C Bristow; Jeffrey D Klausner
Journal:  J Int AIDS Soc       Date:  2014-10-10       Impact factor: 5.396

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.